Alzheimer's disease Other Imaging Findings

Revision as of 14:27, 21 September 2017 by Akshun Kalia (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Alzheimer's disease Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Alzheimer's disease from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic study of choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Alzheimer's disease Other Imaging Findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Alzheimer's disease Other Imaging Findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Alzheimer's disease Other Imaging Findings

CDC on Alzheimer's disease Other Imaging Findings

Alzheimer's disease Other Imaging Findings in the news

Blogs on Alzheimer's disease Other Imaging Findings

Directions to Hospitals Treating Alzheimer's disease

Risk calculators and risk factors for Alzheimer's disease Other Imaging Findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Akshun Kalia M.B.B.S.[2]

Overview

Other imaging studies in Alzheimer's include positron emission tomography (PET) and single photon emission computed tomography (SPECT) scan. PET and SPECT scan are not routinely done in Alzheimer's disease. However, patients with atypical presentation may be evaluated with either a PET or SPECT scan to assess for any underlying condition. In these patients, use of amyloid β PET scan will reveal lower FDG (fluorine-18 fluorodeoxyglucose) metabolism and higher PiB ([11 C]Pittsburgh compound B) deposition in areas of the brain affected by Alzheimer's disease. On SPECT scan patients with Alzheimer's disease have low relative regional cerebral blood flow (rCBF) in the parietal and prefrontal cortices.

Other Imaging Findings

Other imaging studies include:[1][2][3][4][5][6]

References

  1. Geda, Yonas E. (2012). "Mild Cognitive Impairment in Older Adults". Current Psychiatry Reports. 14 (4): 320–327. doi:10.1007/s11920-012-0291-x. ISSN 1523-3812.
  2. Trollor JN, Sachdev PS, Haindl W, Brodaty H, Wen W, Walker BM (2005). "Regional cerebral blood flow deficits in mild Alzheimer's disease using high resolution single photon emission computerized tomography". Psychiatry Clin. Neurosci. 59 (3): 280–90. doi:10.1111/j.1440-1819.2005.01372.x. PMID 15896221.
  3. Trollor JN, Sachdev PS, Haindl W, Brodaty H, Wen W, Walker BM (2006). "A high-resolution single photon emission computed tomography study of verbal recognition memory in Alzheimer's disease". Dement Geriatr Cogn Disord. 21 (4): 267–74. doi:10.1159/000091433. PMID 16479105.
  4. Ferris SH, de Leon MJ, Wolf AP, Farkas T, Christman DR, Reisberg B, Fowler JS, Macgregor R, Goldman A, George AE, Rampal S (1980). "Positron emission tomography in the study of aging and senile dementia". Neurobiol. Aging. 1 (2): 127–31. PMID 24279935.
  5. Rapoport SI (1986). "Positron emission tomography in normal aging and Alzheimer's disease". Gerontology. 32 Suppl 1: 6–13. PMID 3488245.
  6. Cutler NR (1986). "Cerebral metabolism as measured with positron emission tomography (PET) and [18F] 2-deoxy-D-glucose: healthy aging, Alzheimer's disease and Down syndrome". Prog. Neuropsychopharmacol. Biol. Psychiatry. 10 (3–5): 309–21. PMID 2948218.

Template:WH Template:WS